HK1063789A1 - Chemokine receptor antagonists and methods of use thereof - Google Patents
Chemokine receptor antagonists and methods of use thereofInfo
- Publication number
- HK1063789A1 HK1063789A1 HK04106595A HK04106595A HK1063789A1 HK 1063789 A1 HK1063789 A1 HK 1063789A1 HK 04106595 A HK04106595 A HK 04106595A HK 04106595 A HK04106595 A HK 04106595A HK 1063789 A1 HK1063789 A1 HK 1063789A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- methods
- receptor antagonists
- chemokine receptor
- chemokine
- antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/989,086 US20020169155A1 (en) | 1998-09-04 | 2001-11-21 | Chemokine receptor anagonists and methods of use therefor |
PCT/US2002/036953 WO2003045942A2 (fr) | 1998-09-04 | 2002-11-13 | Antagonistes des recepteurs de la chimiokine et methodes d'utilisation de ces antagonistes |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1063789A1 true HK1063789A1 (en) | 2005-01-14 |
Family
ID=32713949
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK04106595A HK1063789A1 (en) | 2001-11-21 | 2004-09-02 | Chemokine receptor antagonists and methods of use thereof |
HK11108768.0A HK1154504A1 (en) | 2001-11-21 | 2011-08-19 | Chemokine receptor antagonists and methods of use thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK11108768.0A HK1154504A1 (en) | 2001-11-21 | 2011-08-19 | Chemokine receptor antagonists and methods of use thereof |
Country Status (24)
Country | Link |
---|---|
EP (3) | EP2286811B1 (fr) |
JP (5) | JP4889920B2 (fr) |
KR (3) | KR100952767B1 (fr) |
CN (3) | CN1585772B (fr) |
AR (2) | AR037394A1 (fr) |
AT (1) | ATE320431T1 (fr) |
AU (1) | AU2002352772B2 (fr) |
BR (1) | BR0213633A (fr) |
CA (1) | CA2467672C (fr) |
CY (1) | CY1107243T1 (fr) |
DE (2) | DE60209937T4 (fr) |
DK (1) | DK1448566T5 (fr) |
ES (2) | ES2260497T7 (fr) |
HK (2) | HK1063789A1 (fr) |
IL (3) | IL161669A0 (fr) |
MY (2) | MY146601A (fr) |
NO (1) | NO328166B1 (fr) |
NZ (3) | NZ596484A (fr) |
PL (2) | PL217918B1 (fr) |
PT (1) | PT1448566E (fr) |
SG (2) | SG195393A1 (fr) |
SI (1) | SI1448566T1 (fr) |
TW (1) | TWI308568B (fr) |
ZA (1) | ZA200403530B (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002352772B2 (en) * | 2001-11-21 | 2006-10-26 | Kyowa Hakko Kogyo Co., Ltd. | Chemokine receptor antagonists and methods of use thereof |
US7541365B2 (en) | 2001-11-21 | 2009-06-02 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
TWI291467B (en) * | 2002-11-13 | 2007-12-21 | Millennium Pharm Inc | CCR1 antagonists and methods of use therefor |
EP2229356B1 (fr) * | 2007-12-03 | 2011-10-12 | Novartis AG | Dérivés de 4-benzylaminopyrrolidine 1,2-disubstituée comme inhibiteurs de cetp utiles pour le traitement de maladies telles que l'hyperlipidémie ou l'artériosclérose |
TWI431010B (zh) * | 2007-12-19 | 2014-03-21 | Lilly Co Eli | 礦皮質素受體拮抗劑及使用方法 |
CN104292142B (zh) * | 2013-07-17 | 2019-05-14 | 天津大地康和医药技术有限公司 | 一种n-芳基杂环丁烷脱芳基方法 |
CN105237455A (zh) * | 2015-10-14 | 2016-01-13 | 湖南华腾制药有限公司 | 一种3-取代氮杂环丁烷的制备方法 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DD80449A (fr) * | ||||
JPS5250634B2 (fr) | 1971-08-23 | 1977-12-26 | ||
JPS61152673A (ja) | 1984-12-26 | 1986-07-11 | Kyowa Hakko Kogyo Co Ltd | ジベンズ〔b,e〕オキセピン誘導体の製造法 |
US5089496A (en) | 1986-10-31 | 1992-02-18 | Schering Corporation | Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies |
NZ228888A (en) | 1988-04-28 | 1991-12-23 | Schering Corp | Derivatives of piperidine, piperidylidene and piperazine and pharmaceutical compositions |
CA2109702A1 (fr) | 1991-05-23 | 1992-11-26 | Jesse K. Wong | Nouveaux composes du type benzopyridopiperidylidene, compositions, methodes d'obtention industrielles et methodes d'emploi |
JPH06509341A (ja) | 1991-07-23 | 1994-10-20 | シェリング・コーポレーション | 新規ベンゾピリドピペリジリデン化合物、組成物、製造方法および使用方法 |
ES2250964T3 (es) | 1992-11-10 | 2006-04-16 | Genentech, Inc. | Receptor de la quimioquina c-c(c-c ckr-1). |
WO1996031469A1 (fr) * | 1995-04-07 | 1996-10-10 | Novo Nordisk A/S | Nouveaux composes heterocycliques |
AU704825B2 (en) * | 1995-12-15 | 1999-05-06 | Novo Nordisk A/S | Novel method |
CA2319077A1 (fr) * | 1998-01-21 | 1999-07-29 | Yoshisuke Nakasato | Antagonistes du recepteur de chemokine et leurs procedes d'utilisation |
US6509346B2 (en) * | 1998-01-21 | 2003-01-21 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
AU2331199A (en) * | 1998-09-04 | 2000-03-27 | Kyowa Hakko Kogyo Co. Ltd. | Chemokine receptor antagonists and methods of use therefor |
WO2001009137A1 (fr) * | 1999-07-28 | 2001-02-08 | Millennium Pharmaceuticals, Inc. | Antagonistes de recepteur de chemokine et procedes d'utilisation |
ATE319775T1 (de) | 1999-10-20 | 2006-03-15 | Kingspan Holdings Irl Ltd | Zellulärer kunststoff auf basis phenolharz |
TW503427B (en) | 2000-07-25 | 2002-09-21 | Koninkl Philips Electronics Nv | Display tube comprising a mask with vibration damping means |
AU2002352772B2 (en) * | 2001-11-21 | 2006-10-26 | Kyowa Hakko Kogyo Co., Ltd. | Chemokine receptor antagonists and methods of use thereof |
DE102011084910A1 (de) | 2011-10-20 | 2013-04-25 | Wobben Properties Gmbh | Verfahren und Vorrichtung zum Einspeisen elektrischen Stroms in ein elektrisches Netz |
-
2002
- 2002-11-13 AU AU2002352772A patent/AU2002352772B2/en not_active Ceased
- 2002-11-13 DK DK02789725T patent/DK1448566T5/da active
- 2002-11-13 AT AT02789725T patent/ATE320431T1/de active
- 2002-11-13 DE DE60209937T patent/DE60209937T4/de not_active Expired - Lifetime
- 2002-11-13 PL PL369599A patent/PL217918B1/pl unknown
- 2002-11-13 EP EP10012138A patent/EP2286811B1/fr not_active Expired - Lifetime
- 2002-11-13 KR KR1020077024914A patent/KR100952767B1/ko not_active IP Right Cessation
- 2002-11-13 EP EP02789725A patent/EP1448566B3/fr not_active Expired - Lifetime
- 2002-11-13 SG SG2011011095A patent/SG195393A1/en unknown
- 2002-11-13 SG SG200603354-2A patent/SG165152A1/en unknown
- 2002-11-13 CN CN02827426.1A patent/CN1585772B/zh not_active Expired - Fee Related
- 2002-11-13 KR KR1020047007728A patent/KR100919346B1/ko not_active IP Right Cessation
- 2002-11-13 CN CNA2006101054502A patent/CN1911930A/zh active Pending
- 2002-11-13 NZ NZ596484A patent/NZ596484A/xx not_active IP Right Cessation
- 2002-11-13 KR KR1020107000732A patent/KR101001092B1/ko not_active IP Right Cessation
- 2002-11-13 PL PL403800A patent/PL403800A1/pl unknown
- 2002-11-13 PT PT02789725T patent/PT1448566E/pt unknown
- 2002-11-13 IL IL16166902A patent/IL161669A0/xx unknown
- 2002-11-13 EP EP06004401.3A patent/EP1688418B1/fr not_active Expired - Lifetime
- 2002-11-13 SI SI200230327T patent/SI1448566T1/sl unknown
- 2002-11-13 JP JP2003547392A patent/JP4889920B2/ja not_active Expired - Fee Related
- 2002-11-13 BR BR0213633-3A patent/BR0213633A/pt not_active Application Discontinuation
- 2002-11-13 ES ES02789725T patent/ES2260497T7/es active Active
- 2002-11-13 ES ES10012138T patent/ES2396186T3/es not_active Expired - Lifetime
- 2002-11-13 DE DE60209937A patent/DE60209937D1/de not_active Expired - Lifetime
- 2002-11-13 CA CA2467672A patent/CA2467672C/fr not_active Expired - Fee Related
- 2002-11-13 NZ NZ532827A patent/NZ532827A/en not_active IP Right Cessation
- 2002-11-13 NZ NZ585746A patent/NZ585746A/en not_active IP Right Cessation
- 2002-11-13 CN CN201410171050.6A patent/CN104031054A/zh active Pending
- 2002-11-14 MY MYPI20064630A patent/MY146601A/en unknown
- 2002-11-14 AR ARP020104390A patent/AR037394A1/es active IP Right Grant
- 2002-11-14 MY MYPI20024277A patent/MY142646A/en unknown
- 2002-11-14 TW TW091133354A patent/TWI308568B/zh not_active IP Right Cessation
-
2004
- 2004-04-29 IL IL161669A patent/IL161669A/en not_active IP Right Cessation
- 2004-05-10 ZA ZA200403530A patent/ZA200403530B/xx unknown
- 2004-06-15 NO NO20042500A patent/NO328166B1/no not_active IP Right Cessation
- 2004-09-02 HK HK04106595A patent/HK1063789A1/xx not_active IP Right Cessation
-
2006
- 2006-06-05 CY CY20061100740T patent/CY1107243T1/el unknown
-
2007
- 2007-02-06 IL IL181191A patent/IL181191A/en not_active IP Right Cessation
-
2010
- 2010-05-06 JP JP2010106678A patent/JP2010229136A/ja active Pending
-
2011
- 2011-08-19 HK HK11108768.0A patent/HK1154504A1/xx not_active IP Right Cessation
-
2013
- 2013-04-24 AR ARP130101374A patent/AR090829A2/es unknown
- 2013-05-13 JP JP2013101580A patent/JP5878494B2/ja not_active Expired - Fee Related
-
2014
- 2014-12-02 JP JP2014244379A patent/JP5936669B2/ja not_active Expired - Fee Related
-
2016
- 2016-03-01 JP JP2016039332A patent/JP2016138122A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1060727A1 (en) | Antagonists of mcp-1 function and methods of use thereof | |
HK1060728A1 (en) | Antagonists of mcp-1 function and methods of use thereof | |
PT1379504E (pt) | Derivados bipiperidinilo e sua utilização como inibidores de receptores de quimioquinas | |
EP1541585A4 (fr) | Antagoniste de cxcr4 et son utilisation | |
AU5716901A (en) | G protein coupled receptor (gpcr) agonists and antagonists and methods of activating and inhibiting gpcr using the same | |
EP1608318A4 (fr) | Antagonistes cxcr4 et leurs procedes d'utilisation | |
IL161329A0 (en) | Benzamide and heteroarylamide as p2x7 receptor antagonists | |
AU2002360400A8 (en) | Construction and use of micro-electrode arrays | |
HK1154504A1 (en) | Chemokine receptor antagonists and methods of use thereof | |
IL152700A0 (en) | Substituted 1-aminoalkyl-lactams and their use as muscarinc receptor antagonists | |
IL158701A0 (en) | Novel use of nk3 receptor antagonist | |
HUP0203371A3 (en) | Adenosine receptor antagonists and methods of making and using the same | |
AU2003277215A8 (en) | Novel neurokinin antagonists and methods of use thereof | |
IL198759A (en) | Use of 3gal receptor antagonists to prepare medications to treat depression and / or anxiety | |
AU2003260072A8 (en) | Antagonists of chemokine receptors | |
AU2002351175A8 (en) | Novel human g-protein coupled receptor, hgprbmy31, and variants and methods of use thereof | |
HUP0401535A3 (en) | Somatostatin antagonists and their use | |
AU3958902A (en) | Crf receptor antagonists and methods relating thereto | |
AU6503900A (en) | Chemokine receptor antagonists and methods of use therefor | |
AU2002363938A8 (en) | Methods and use of motoneuronotropic factors | |
AU6389900A (en) | Chemokine receptor antagonists and methods of use therefor | |
AU2003247052A1 (en) | Mcp-1 receptor antagonists and method of use thereof | |
PL370367A1 (en) | Ccr-3 receptor antagonists v | |
AU2003300396A8 (en) | Chemokine antagonists and uses thereof | |
EP1324763A4 (fr) | Agonistes et antagonistes de stat3 et applications therapeutiques de ceux-ci |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20151113 |